Bellicum Pharmaceuticals, Inc.
BLCM · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $2 | $6 | $1 | $7 |
| % Growth | -75.8% | 1,140% | -93% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2 | $6 | $1 | $7 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $23 | $24 | $39 | $65 |
| G&A Expenses | $6 | $7 | $16 | $30 |
| SG&A Expenses | $6 | $7 | $16 | $30 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $28 | $31 | $55 | $95 |
| Operating Income | -$27 | -$25 | -$52 | -$87 |
| % Margin | -1,798.7% | -401.1% | -10,338.4% | -1,223.1% |
| Other Income/Exp. Net | $2 | $15 | -$10 | -$25 |
| Pre-Tax Income | -$25 | -$10 | -$8 | -$112 |
| Tax Expense | $0 | -$0 | $1 | $14 |
| Net Income | -$25 | -$10 | -$9 | -$126 |
| % Margin | -1,664.9% | -154.5% | -1,723.8% | -1,765.3% |
| EPS | -0.81 | -0.83 | -1.5 | -26.92 |
| % Growth | 2.4% | 44.7% | 94.4% | – |
| EPS Diluted | -0.81 | -0.83 | -1.5 | -26.92 |
| Weighted Avg Shares Out | 31 | 12 | 6 | 5 |
| Weighted Avg Shares Out Dil | 31 | 12 | 6 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $0 | $0 | $3 | $4 |
| Depreciation & Amortization | -$2 | $1 | -$2 | $19 |
| EBITDA | -$27 | -$24 | $2 | -$87 |
| % Margin | -1,798.7% | -392.7% | 478.2% | -1,223.1% |